Literature DB >> 133008

Role of adenosine deaminase in lymphocyte proliferation.

T Hovi, J F Smyth, A C Allison, S C Williams.   

Abstract

Activity of adenosine deaminase (ADA), an enzyme known to be deficient in some patients with severe combined immunodeficiency, increased three-fold within a 24-hour exposure of human peripheral blood lymphocytes to phytohaemagglutinin (PHA) in culture. This increase took place before the onset of DNA synthesis. Increased levels of ADA activity were also observed in lymphocytes incubated with pokeweed mitogen (PWM) for 60 hr. DNA synthesis induced by PHA, PWM or mixed lymphocyte cultures (MLC) was strongly inhibited by adenosine at concentrations of 10(-4) M or higher when human peripheral blood lymphocytes were cultured in a medium supplemented with horse serum, which lacks ADA. 10(-6)-10(-8) M coformycin, a potent inhibitor of ADA, inhibited PHA-, PWM- and MLC-induced DNA synthesis to a variable extent, whereas thymidine incorporation induced by Salmonella lipopolysaccharide (LPS) in mouse spleen cell cultures was strongly inhibited (by 75% or more) by 10(-6) M coformycin. Combination of 10(-7)-10(-8) M coformycin and 10(-4)-10(-5) M adenosine synergistically inhibited mitogen- or MLC-induced DNA synthesis in human and mouse lymphocyte cultures. These results, together with observations on children with ADA deficiency, provide evidence that adenosine deaminase is highly important for lymphocyte proliferation. Human peripheral blood lymphocytes incubated with PHA, 10(-5) M adenosine and 10(-7) M coformycin showed some cytotoxicity whereas the rate of 51Cr release from normal lymphocytes was not modified by the drugs. These findings suggest that in vivo clones of lymphocytes responding to specific antigens might be eliminated by coformycin, which may prove to be useful as a specific immunosuppressive agent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 133008      PMCID: PMC1538382     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes.

Authors:  T Hovi; A C Allison; J Allsop
Journal:  FEBS Lett       Date:  1975-07-15       Impact factor: 4.124

2.  A STUDY OF THE TISSUE DISTRIBUTION OF ADENOSINE DEAMINASE IN SIX MAMMAL SPECIES.

Authors:  T G BRADY; C I O'DONOVAN
Journal:  Comp Biochem Physiol       Date:  1965-01

3.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

4.  The deaminases of adenosine and adenylic acid in blood and tissues.

Authors:  E J Conway; R Cooke
Journal:  Biochem J       Date:  1939-04       Impact factor: 3.857

5.  Adenosine deaminase.

Authors:  T Brady
Journal:  Biochem J       Date:  1942-06       Impact factor: 3.857

6.  Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate.

Authors:  G Wolberg; T P Zimmerman; K Hiemstra; M Winston; L C Chu
Journal:  Science       Date:  1975-03-14       Impact factor: 47.728

7.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

8.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

9.  5-Phosphoribosyl pyrophosphate synthetase from Ehrlich ascites tumor cells.

Authors:  P C Wong; A W Murray
Journal:  Biochemistry       Date:  1969-04       Impact factor: 3.162

10.  Adenosine deaminase activity in leukaemia.

Authors:  J F Smyth; K R Harrap
Journal:  Br J Cancer       Date:  1975-05       Impact factor: 7.640

View more
  38 in total

1.  Lymphocytic adenosine deaminase activity in typhoid fevers.

Authors:  S N Khosla; D Kumar; V Singh
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  Cell kinetics in the spleen of Ehrlich ascites tumor-bearing mice.

Authors:  D Suciu; Z Uray
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978

3.  Adenosine deaminase activity in thymus and other human tissues.

Authors:  A Adams; R A Harkness
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

4.  Neuroinflammation after neonatal hypoxia-ischemia is associated with alterations in the purinergic system: adenosine deaminase 1 isoenzyme is the most predominant after insult.

Authors:  Victor Camera Pimentel; Maria Beatriz Moretto; Mariana Colino Oliveira; Daniela Zanini; Ana Maria Sebastião; Maria Rosa Chitolina Schetinger
Journal:  Mol Cell Biochem       Date:  2015-02-27       Impact factor: 3.396

5.  Evaluation of adenosine deaminase assay for analyzing T-lymphocyte density in vitro.

Authors:  Rani Poonam Kainthla; Rajpal Singh Kashyap; Sweta Prasad; Hemant J Purohit; Giridhar M Taori; Hatim F Daginawala
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Nov-Dec       Impact factor: 2.416

6.  Oxidative Stress Biomarkers and Adenosine Deaminase over the Alopecic Area of the Patients with Alopecia Areata.

Authors:  Perihan Öztürk; Özer Arıcan; Ergül Belge Kurutaş; Kamil Mülayim
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

7.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity.

Authors:  T S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

8.  Aerobic glycolysis and lymphocyte transformation.

Authors:  D A Hume; J L Radik; E Ferber; M J Weidemann
Journal:  Biochem J       Date:  1978-09-15       Impact factor: 3.857

Review 9.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.